No evidence of chromosome damage in chronic obstructive pulmonary disease (COPD)

Marta Casella, Massimo Miniati1, Simonetta Monti1, Fabrizio Minichilli2, Fabrizio Bianchi2 and Silvana Simi*

Cell Biology and Cytogenetics Unit, 1Pulmonary Unit and 2Epidemiology Unit, Institute of Clinical Physiology, National Research Council, Pisa, Italy

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in industrialized countries. It is characterized by a progressive airflow limitation resulting from an abnormal inflammatory response of the lungs to inhaled gases and particles. Since oxidative stress is thought to play a role in COPD, and since increased oxidative stress is associated with chromosomal instability in several diseases, we investigated whether such relationship also exists in COPD. Whole blood lymphocytes from 49 COPD patients and 48 age- and sex-matched controls were cultivated in vitro and cytogenetic damage was evaluated by micronucleus (MN) and sister-chromatid-exchange (SCE) assays. In patients with COPD, MN frequency was not significantly different from that of controls. Similarly, SCE frequency did not differ in the two groups suggesting no disturbance in DNA replication. Unlike other diseases characterized by oxidative stress, COPD does not appear to be associated with DNA damage.

Introduction

Chronic obstructive pulmonary disease (COPD) is a major leading cause of chronic morbidity and mortality in industrialized countries, and is supposed to become the third leading cause of death and fifth cause of disability by the Year 2020 (1,2).

COPD is characterized by a progressive, not fully reversible, airflow limitation resulting from an abnormal inflammatory response of the lungs to particles and gases (2,3). The pathogenesis of COPD is not fully understood, but epidemiological studies have shown a strict correlation with environmental and host factors (3). The main environmental factor is exposure to cigarette smoke (CS). Yet, only a minority of smokers develop COPD. Whole blood lymphocytes from 49 COPD patients and 48 age- and sex-matched controls were cultivated in vitro and cytogenetic damage was evaluated by micronucleus (MN) and sister-chromatid-exchange (SCE) assays. In patients with COPD, MN frequency was not significantly different from that of controls. Similarly, SCE frequency did not differ in the two groups suggesting no disturbance in DNA replication. Unlike other diseases characterized by oxidative stress, COPD does not appear to be associated with DNA damage.

Materials and methods

Subjects

The study sample consisted of 97 subjects who were evaluated at the outpatient clinic of our institution between November 27, 2002 and January 31, 2004. All subjects were examined uniformly according to a standardized protocol including clinical history, physical examination, spirometry and chest radiography. Criteria for patient recruitment were a firm diagnosis of COPD; airflow obstruction as manifested by a ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) <70% and FEV1 ≤70% of normal predicted values (6); no significant reversibility of airflow obstruction (change in FEV1 ≤12% after bronchodilator); smoking history ≥20 pack-years. Patients were excluded from the study if they had an established diagnosis of asthma, other obstructive syndromes, lung cancer, or if they had an acute exacerbation in the 4 weeks preceding recruitment.

The control group consisted of individuals who had no evidence of airflow obstruction (FEV1/FVC > 70% and FEV1 ≥ 80% predicted). Controls were selected to match patients with COPD for age, gender and cumulative smoking history. None of them reported occupational exposure or history of chronic lung disease, and none had acute respiratory infection in the 4 weeks preceding the study entry.

On interviewing the subjects recruited to the study, care was taken to identify any comorbid condition which may per se induce genotoxic damage.

An informed written consent was obtained from all subjects, and the protocol was approved by the local ethics committee.

Cell culture

Peripheral blood was collected in heparinized tubes. Lymphocyte cultures were set up by mixing 0.5 ml of whole blood with 4.5 ml of RPMI-1640 medium containing 15% fetal calf serum, antibiotics (5 U/ml penicillin and 5 μg/ml streptomycin) and phytohaemagglutinin (PHA, 1.5% of the final culture medium) (all reagents from Gibeo, Life Technologies, Italy) according to standard techniques (24). Duplicate cultures were incubated at 37°C in a humidified atmosphere with 5% CO2 and maintained for 72 h.

MN test

Cytoskeletal B (3 μg/ml, Sigma Chemical Co., St Louis, MO) was added after 44 h of culture to block cytokinesis, allowing identifying lymphocytes dividing in culture. Cells that have undergone the first mitosis are thus recognized as binucleated cells and are selectively screened for the presence of MN (25). Cell harvesting, hypotonic treatment, fixation and slide preparation were performed according to standard procedures (22,24). MN were scored blindly in 1000 binucleated cells, following standard criteria (26), and the frequency was expressed as the number of binucleated cells presenting one or more MN per 1000 cells. The nuclear division index (NDI) was calculated according to the formula NDI = [(Mn + 2Bn + 3Trn + 4Ten)/(Mn + Bn + Trn + Ten)].

As an association between oxidative stress and chromosome instability has been reported in a variety of chronic diseases such as Parkinson’s disease (13), coronary artery disease (14), Alzheimer disease (15), Raynaud’s phenomenon (16), diabetes mellitus (17,18) and hypercholesterolemia (19), the present study was aimed at establishing whether genome DNA damage is also present in COPD. Cytogenetic endpoints are sensitive biomarkers that are widely accepted to evaluate chromosome damage (20–23). To this end, we measured the relative frequency of micronuclei (MN) and sister-chromatid-exchanges (SCE) in a group of patients with established COPD and in a matched group of non-diseased subjects.
**Table I.** Baseline characteristics of the study sample

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>COPD (n = 49)</th>
<th>Controls (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>44 (90)</td>
<td>42 (87)</td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>5 (10)</td>
<td>6 (13)</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>64.8 ± 8.1</td>
<td>65.7 ± 6.2</td>
</tr>
<tr>
<td>Smoking habit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pack-years (mean ± SD)</td>
<td>47.1 ± 16.1</td>
<td>42.3 ± 13.7</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
<td>27 (55)</td>
<td>25 (52)</td>
</tr>
<tr>
<td>Former smokers, n (%)</td>
<td>22 (45)</td>
<td>23 (48)</td>
</tr>
<tr>
<td>Lung function tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1/FVC % (mean ± SD)</td>
<td>52 ± 11</td>
<td>76 ± 4</td>
</tr>
<tr>
<td>FEV1 % pred (mean ± SD)</td>
<td>53 ± 13</td>
<td>94 ± 12</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None, n (%)</td>
<td>15 (31)</td>
<td>18 (37)</td>
</tr>
<tr>
<td>Hypercholesterolemia, n %</td>
<td>14 (29)</td>
<td>14 (29)</td>
</tr>
<tr>
<td>Ischemic heart disease, n %</td>
<td>6 (12)</td>
<td>17 (35)</td>
</tr>
<tr>
<td>Systemic arterial hypertension, n %</td>
<td>17 (35)</td>
<td>19 (40)</td>
</tr>
<tr>
<td>Other cardiovascular disorders, n %</td>
<td>9 (18)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>7 (14)</td>
<td>5 (10)</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None, n (%)</td>
<td>15 (31)</td>
<td>21 (44)</td>
</tr>
<tr>
<td>Bronchodilators, n (%)</td>
<td>19 (39)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Cardiovascular therapy, n (%)</td>
<td>24 (49)</td>
<td>26 (54)</td>
</tr>
<tr>
<td>Statines, n (%)</td>
<td>10 (29)</td>
<td>9 (19)</td>
</tr>
</tbody>
</table>

n represents the number of individuals presenting a certain factor. Values are expressed as number and percentage (in brackets), or as mean ± SD.

where Mn, Bn, Tn and Ten indicate the number of mono, bi, tri and tetraneutaled cells, respectively.

**SCE test**

A total of 6 μg/ml of 5-bromodeoxy-uridine (BrdU; Sigma-Aldrich, Steinheim, Germany) were added after 24 h of culture and the FPG method was used to differentially stain sister chromatids (27). Colcemid (0.05 μg/ml; Sigma-Aldrich, Steinheim, Germany) was added during the last 2 h and a minimum of 30 well-stained second division metaphases was scored per individual.

The proliferation index (PI) was calculated from BrdU-labeled metaphases according to the formula PI = [(M1 + 2M2 + 3M3)/M1 + M2 + M3], where M1, M2 and M3 represent the number of first, second and third metaphases, respectively.

**Statistical analysis**

Differences between demographic and clinical characteristics were assessed between COPD patients and controls by contingency tables for categorical variables and χ²-test. As the frequencies of MN and SCE were normally distributed both in the two diagnostic groups, parametric one-way analysis of variance and unpaired t-test were used to score the differences in the frequencies of MN and SCE among each category of the following variables: presence/absence of COPD, sex, smoking habits, medications and comorbidities. Pearson’s coefficient was used in evaluating correlations between MN or SCE frequencies and continuous variables (age, FEV1 and pack-years of smoking). Two-tailed P-values < 0.05 were considered statistically significant throughout. Statistical analysis was performed with STATA 8 software (StataCorp, College Station, TX).

**Results**

The baseline characteristics of the study sample are reported in Table I.

There was no significant difference between patients with COPD and controls as regards age, gender and pack-years of smoking. Similarly, there was no difference between the two diagnostic groups as to the prevalence of comorbid conditions except for ischemic heart disease whose prevalence was significantly higher (P < 0.05) in controls than in COPD patients (Table I).

In patients with COPD, MN averaged 11.8 ± 4.6 and were not significantly different from those measured in controls (10.9 ± 3.6). To assess the effect of comorbidity on MN frequency, COPD patients and controls were further divided in two subgroups according to the presence or absence of comorbid conditions. As shown in Figure 2, there was no significant difference in MN frequency across the four subgroups. The number of MN averaged 11.7 ± 5.3 in patients with COPD and no comorbidity and 10.3 ± 3.1 in controls with no comorbidity (P = 0.38).
**Discussion**

Monitoring DNA damage in pathologies is increasingly performed, as it may add another dimension to their clinical manifestation and could represent a potential target of therapeutic intervention.

Different kinds of DNA damage, ranging from oxidized bases to gross DNA changes, such as chromosome breaks which may drive the formation of MN, have been related to abnormal oxidative stress, which also underlie several pathologies (13–19). COPD is characterized by chronic oxidative stress as well, and very recently the presence of DNA damage, measured by the comet test, has been reported (28).

In our study, instead, using MN and SCE frequencies as biomarkers, we did not find any evidence of genomic alterations.

It has been reported that when oxidative stress is prolonged, cells may undergo apoptosis or direct necrosis (29,30) and recently, increased apoptosis have been demonstrated in lymphocytes obtained from the airways of COPD (31–33). Cells characterized by oxidative stress could give rise to MN, as a result of DNA damage, but would also be prone to be eliminated by an efficient apoptosis pathway, thus explaining our failure to find genomic damage in COPD patients.

We also failed to find any modulation of MN and SCE frequency by smoking habits: in fact there was no statistically significant difference in MN frequency between current and former smokers (P = 0.29). As the association between smoking and lung cancer has been firmly established (34), the genotoxic effects of CS in *in vitro*/*ex vivo* experiments are not so clear, despite the well known mutagenic and carcinogenic potential of many components of the CS.

In fact, many studies report unexpected negative results (35) and sometime smokers present lower MN frequency than non-smokers (36). Possible explanations for this lack of effects has been proposed, such as low sensitivity of MN test, lower effective exposure of lymphocytes to CS than other organs as lung, low survival of damaged cells (apoptosis or necrosis), delay in the cell cycle giving rise to false negative results (37). Our present data of PI and NDI seem to exclude this latter explanation.

A huge literature is also present on non-human systems. As recently reviewed by DeMarini (38), CS or its condensate is able to induce SCE and MN in rodent V79 and CHO cells *in vitro* and in the bone marrow, lung and erythrocytes of mice/rats after *in vivo* exposure to CS. Transplacental effects have also been reported: mice born of exposed mothers exhibit a high frequency of MN in the liver and blood cells (38,39).

Interactions may also occur among the >4000 CS components and protective substances may also mask the genotoxicity of this complex mixture: CS has been shown to inhibit the required metabolic activation of several mutagens (40), and the mutagenicity of three major nitrosamines in *Salmonella* and rodent cells (41). Individual CS susceptibility may also be strongly modulated by genetic factors. It is well known the involvement of cytochrome P450 polymorphism in lung carcinogenesis: *CYP2D6* gene is suspected because of its activation of tobacco genotoxins (42), while genetic polymorphism of *CYP2A6* was associated with cancer susceptibility caused by smoking (43,44). A genetic characterization of COPD patients could help identifying the so called ‘susceptible’ smokers, who will develop irreversible COPD (45).

The multifactorial nature of COPD itself (where several genes, genetic polymorphisms, required therapies, multiple exposures to CS) may alter and modulate the phenotype of this pathology and can account for the absence of detectable genetic damage.

Also the elder age of individuals from our populations can be considered a further contributing factor: aging has been associated with a reduction of regenerative capacity of cells, and an increased rate of apoptosis has been observed in senescent endothelial cells (46).

Furthermore, COPD is a highly regional disease in its clinical manifestations (47) whereas MN and SCE assays are
References


Received on December 20, 2005; revised on February 19, 2006; accepted on February 28, 2006